Hayfin Capital Management Completes Credit Agreement Amendment with ADMA Biologics
ADMA Biologics, a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, amended the terms of its existing senior credit facility with Hayfin Capital Management, which matures in March 2027.